Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias

Overview

This is a prospective observational cohort study of haploidentical transplantation with post-transplant cyclophosphamide for acute leukemias using reduced intensity conditioning for acute myeloid leukemia (AML) and myeloablative conditioning for acute lymphoblastic leukemia (ALL).

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: April 2021

Detailed Description

Hematopoietic stem cell transplantation (HSCT) is the most effective treatment for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), with the lowest rates of relapse. Fertility rate in Brazil is falling, and only 25% of people born today will have a matched sibling donor. On the other hand, currently donor non-related to about 50% of patients enrolled in Brazilian Receptor Registry (REREME). Consequently, at least 35% of patients won't have a matched donor. The haploidentical transplantation is defined as a partially matched hematopoietic cell transplantation, using a partially matched family donor (parent, sibling or child). Haploidentical transplantation activity is growing worldwide, with results comparable matched unrelated donors. The objective of this study is to test the feasibility of haploidentical transplantation with post transplant cyclophosphamide for acute leukemias in a Brazil.

Interventions

  • Procedure: Haploidentical Stem Cell Transplantation
    • Haploidentical Stem Cell Transplantation from a related donor (partially matched sibling, father, mother, son or daughter).

Arms, Groups and Cohorts

  • Group A: Acute Lymphoblastic Leukemia
    • Haploidentical Stem Cell Transplantation with Post Transplant Cyclophosphamide (PTCy) Preferred conditioning: Total Body Irradiation 1200 cGy (TBI1200) + Fludarabine 120 mg/m2 (Flu120) Alternative conditionings: Melphalan 100-140 mg/m2 (Mel100-140) + Fludarabine 160 mg/m2 (Flu160) + Total Body Irradiation 200 cGy (TBI200) Busulfan 9.6 mg/kg (Bu9.6) + Fludarabine 150 mg/m2 (Flu150) + TBI200 Graft versus host disease Prophylaxis: Post-Transplant Cyclophosphamide (PTCy) + Tacrolimus (FK) or Cyclosporin (CSA) + Mycophenolate Mofetil (MMF)
  • Group B: Acute Myeloid Leukemia
    • Haploidentical Stem Cell Transplantation with Post Transplant Cyclophosphamide (PTCy) Preferred Conditioning: Mel100-140 + Flu160 + TBI200 Alternative conditionings: Bu9,6 + Flu150 + TBI200 Cyclophosphamide 29 mg/kg + Flu150 + TBI200 Graft versus host disease Prophylaxis: PTCy + FK or CSA + MMF

Clinical Trial Outcome Measures

Primary Measures

  • Overall Survival
    • Time Frame: 1 year
    • 1-year overall survival. Survival curves will be estimated by Kaplan-Meier methodology.

Secondary Measures

  • Cumulative incidence of leukemia relapse
    • Time Frame: 5 years
    • Relapse will be defined by reappearance of Leukemic Cells in bone marrow (>5%) or peripheral blood (>1%). Risk factors for leukemia relapse will be estimated by extended Cox Model for competing risks (Fine & Gray model). Competing event will be defined as death in remission.
  • Transplant Related Mortality
    • Time Frame: 6 months
    • Transplant-related mortality (TRM) will be defined as death in remission. Risk factors for TRM will be estimated by extended Cox Model for competing risks (Fine & Gray model). Competing event will be defined as leukemia relapse.
  • Cumulative Incidence of acute Graft Versus Host Disease
    • Time Frame: 5 years
    • Acute graft versus host disease will be diagnosed and graded by modified Glucksberg criteria. Risk factor for acute graft versus host disease will be estimated by extended Cox Model for competing risks (Fine & Gray model). Cumulative incidence curves will be estimated by Gray methodology.
  • Cumulative Incidence of chronic Graft Versus Host Disease
    • Time Frame: 5 years
    • Chronic graft versus host disease will be diagnosed and graded by National Institute of Health Consensus (NIH Consensus). Risk factor for chronic graft versus host disease will be estimated by extended Cox Model for competing risks (Fine & Gray model). Cumulative incidence curves will be estimated by Gray methodology.
  • Cumulative Incidence of Infectious Complications
    • Time Frame: 1 year
    • Cumulative incidence of viral, fungal and bacterial infections. Subgroups will be compared by Cox Model for competing risks (Fine & Gray model). Cytomegalovirus reactivation will be analyzed by multiple events Cox Model.

Participating in This Clinical Trial

Inclusion Criteria

  • Acute lymphoblastic leukemia or acute myeloid leukemia Exclusion Criteria:

  • Severe comorbidities – Second transplant

Gender Eligibility: All

Minimum Age: 1 Year

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Leonardo Javier Arcuri
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Leonardo Javier Arcuri, Physician – Instituto Nacional de Cancer, Brazil
  • Overall Official(s)
    • Leonardo J Arcuri, MD, Principal Investigator, Instituto Nacional de Cancer
  • Overall Contact(s)
    • Leonado J Arcuri, MD, +55(21)32071304, leonardojavier@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.